Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Petrylak Discusses the Isotope Radium-223

Daniel P. Petrylak, MD
Published: Tuesday, Feb 28, 2012

Daniel P. Petrylak, MD, Professor of Medicine, Co-Leader of Prostate Cancer, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the new isotope agent radium-223 (Alpharadin).

The ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial that investigated radium-223 for prostate cancer with bone metastases was the first trial to demonstrate an overall survival benefit for an isotopic agent. This agent is set apart by its tolerability when combined with hormonal therapies and chemotherapy.

Radium-233 combines well with docetaxel, something that sets it apart from other approved radiopharmaceuticals. The ALSYMPCA trial investigated the agent in patients that were post – or deemed unfit to receive docetaxel.

Further studies need to be done to determine how to sequence these drugs in a manner that creates a minimum amount of toxicities.

SELECTED
LANGUAGE
Daniel P. Petrylak, MD, Professor of Medicine, Co-Leader of Prostate Cancer, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the new isotope agent radium-223 (Alpharadin).

The ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial that investigated radium-223 for prostate cancer with bone metastases was the first trial to demonstrate an overall survival benefit for an isotopic agent. This agent is set apart by its tolerability when combined with hormonal therapies and chemotherapy.

Radium-233 combines well with docetaxel, something that sets it apart from other approved radiopharmaceuticals. The ALSYMPCA trial investigated the agent in patients that were post – or deemed unfit to receive docetaxel.

Further studies need to be done to determine how to sequence these drugs in a manner that creates a minimum amount of toxicities.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x